Tag Archives: Health

TRADE Sexual Health – 160 People Tested at Leicester Pride 2012

Trade Sexual Health is a HIV & AIDS prevention charity based in Leicester for people living in Leicester, Leicestershire and Rutland.

They provide free and confidential advice and support to anyone who identifies as gay, lesbian, bisexual, men who has sex with men or women who has sex with women.

The city of Leicester has the fastest-rising HIV rate in the east Midlands and the sixth-highest in the country.

Leicester GU accompanied Trade on site providing HIV tests for the community alongside other activities.  LASS would like to say a big thank you, and congratulate Leicester GU with Trade for achieving 160 Kwik Prick, Rapid HIV Tests for the community.  Here’s an update on their day, from Trade:

Breaking Record! 160 People Tested at Leicester Pride 2012

Now at the forefront of sexual health, Trade Sexual Health joined forces once again with Leicester GUM Clinic to provide the Trade Health & Wellbeing Marquee at Leicester Pride 2012!

Our nationally recognised Trade GU clinic at Leicester Pride tested a record 160 people. All 160 had a full sexual health screening beating last year’s 136. With infection rates increasing, and undiagnosed HIV on the rise, this was a fantastic achievement, Thank you to the 160 people who tested.

Pride goers took part in fitness classes, had health checks, accessed information, booked in for a free massage and visited a host of other health and wellbeing stands in the Marquee. As usual Trade brought along a load of resources and goodies and we launched our new health campaign raising awareness of STIs. The willy sweets promoting this campaign seemed to attract a lot of attention.

We managed to give out roughly 3,000 free condoms to those present on the day.

Thank you to everyone who came along; to Leicester Pride, Leicester GU, sponsors, all the volunteers, staff and our committed Board of Trustees, for a fantastic day.
We are confident that we will build on this success and provide an even bigger and better Trade Marquee next year.

- Tradesexualhealth.com

If that wans’t enough Gay Pride for you, we were there too! – Click this to find out more.

STAY UPDATED
Follow LASS on Twitter
or subscribe via email

Discussions with a Dietitian: Fruit & Vegetables

Each month, a registered dietician from the NHS, visits LASS to offer helpful advice and information on food nutrition and healthy eating for people who live with HIV.  Our next is session is in a week, Friday 17th August (12:00 noon) and will focus on Fruit & Vegetables.  This is an opportunity to ask questions and speak with the dietitian directly about any concerns you may have.

What we eat affects our overall health. Food can help the body to fight infections. It also provides energy so that we can carry on leading active lives.

Eating healthily can prevent weight loss or weight gain. It can lower blood sugar and cholesterol levels, which helps to prevent diabetes and heart disease. Food can also help control some of the side-effects of medication.

This all means that good nutrition is an important part of living well with HIV, we do hope you’re able to join us next week.

STAY UPDATED
Follow LASS on Twitter
or subscribe via email

A Cure for HIV/AIDS Has Got a Step Closer!

Listen to this article instead


HIV is an exceptional adversary. It is more diverse than any other virus, and it attacks the very immune cells that are meant to destroy it. If that wasn’t bad enough, it also has a stealth mode. The virus can smuggle its genes into those of long-lived white blood cells, and lie dormant for years. This “latent” form doesn’t cause disease, but it’s also invisible to the immune system and to anti-HIV drugs.

When the virus awakens, it can trigger new bouts of infection – a risk that forces HIV patients to stay on treatments for life. It’s clear that if we’re going to cure HIV for good, we need some way of rousing these dormant viruses from their rest and eliminating them.

Now, a cure for HIV/AIDS has got a step closer after scientists found that a common cancer drug can purge the disease as it lies dormant in the body.  Current treatments are effective at reducing levels of the disease in the bloodstream – but a drug that can ‘knock out’ the disease when it lies dormant is thought to be key to a cure.

A team of US scientists led by David Margolis has found that vorinostat – a drug used to treat lymphoma – can do exactly that. It shocks HIV out of hiding. While other chemicals have disrupted dormant HIV within cells in a dish, this is the first time that any substance has done the same thing in actual people.

At this stage, Margolis’s study just proves the concept – it shows that disrupting HIV’s dormancy is possible, but not what happens afterwards. The idea is that the awakened viruses would either kill the cell, or alert the immune system to do the job. Drugs could then stop the fresh viruses from infecting healthy cells. If all the hidden viruses could be activated, it should be possible to completely drain the reservoir. For now, that’s still a very big if, but Margolis’s study is a step in the right direction.

HIV enters its dormant state by convincing our cells to hide its genes. It recruits an enzyme called histone deacetylase (HDAC), which ensures that its genes are tightly wrapped and cannot be activated. Vorinostat, however, is an HDAC inhibitor – it stops the enzyme from doing its job, and opens up the genes that it hides.

It had already proven its worth against HIV in the lab. Back in 2009, three groups of scientists(including Margolis’ team) showed that vorinostat could shock HIV out of cultured cells, producing detectable levels of viruses when they weren’t any before.

To see if the drug could do the same for patients, the team extracted white blood cells from 16 people with HIV, purified the “resting CD4 T-cells” that the virus hides in, and exposed them to vorinostat. Eleven of the patients showed higher levels of HIV RNA (the DNA-like molecule that encodes HIV’s genes) – a sign that the virus had woken up.

Eight of these patients agreed to take part in the next phase. Margolis gave them a low 200 milligram dose of vorinostat to check that they could tolerate it, followed by a higher 400 milligram dose a few weeks later. Within just six hours, he found that the level of viral RNA in their T-cells had gone up by almost 5 times.

These results are enough to raise a smile, if not an outright cheer. We still don’t know how extensively vorinostat can smoke HIV out of hiding, or what happens to the infected cells once this happens. At the doses used in the study, the amount of RNA might have gone up, but the number of actual viral particles in the patients’ blood did not. It’s unlikely that the drug made much of a dent on the reservoir of hidden viruses, so what dose should we use, and over what time?

Vorinostat’s actions were also very varied. It did nothing for 5 of the original 16 patients. For the 8 who actually got the drug, some produced 10 times as much viral RNA, while others had just 1.5 times more. And as you might expect, vorinostat comes with a host of side effects, and there are concerns that it could damage DNA. This study could be a jumping point for creating safer versions of the drug that are specifically designed to awaken latent HIV, but even then, you would still be trying to use potentially toxic drugs to cure a long-term disease that isn’t currently showing its face. The ethics of doing that aren’t clear.

Steven Deeks, a HIV researcher from the University of California San Francisco, talks about these problems and more in an editorial that accompanies the new paper. But he also says that the importance of the study “cannot be over­stated, as it provides a rationale for an entirely new approach to the management of HIV infection”.

Progress is being made every day, don’t believe us? – Check out the related articles below!

Original Articles via Discover Magazine and Mail Online

STAY UPDATED
Follow LASS on Twitter
or subscribe via email

Together We Will End AIDS

Entitled Together we will end AIDS, the new UNAIDS report contains the latest data on numbers of new HIV infections, numbers of people receiving antiretroviral treatment, AIDS-related deaths and HIV among children. It highlights new scientific opportunities and social progress which are bringing the world closer to UNAIDS vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths.

The report also gives an overview of international and domestic HIV investments and the need for greater value for money and sustainability.

Calling for global solidarity and shared responsibility, the UNAIDS report contains commentaries from global and community leaders as well as people living with and affected by HIV.

Download here

Link to UNAIDS Campaign 

STAY UPDATED
Follow LASS on Twitter
or subscribe via email

Another view on Angels in America

The drama in Angels in America seems like a nightmare from a long time ago, but still stands as a challenge to change our attitudes to HIV.

In Angels in America, HIV is the spur that causes the truth to come out. The original play by Tony Kushner is set in 1980s New York at the height of the Aids epidemic. Not only does HIV reveal the truth about all the characters and their sex lives, it also (through each person’s attitude to the disease) tells us a huge amount about society in general.

It’s a complex story. Louis leaves his gay lover Prior, who has been diagnosed with Aids, because he can’t cope with it all. In a separate strand, Roy, an apparently rightwing lawyer, is gay yet extremely homophobic. He is dying but he won’t let what’s killing him be called Aids; he euphemistically terms it “liver cancer”. And Prior is bullied by angels, who tell him to be a prophet – but he rebels, retorting that all people with HIV and Aids want is to be “citizens”.

The play has now been turned into an opera by Péter Eötvös. When I saw it recently at London’s Barbican, I wasn’t convinced that the music brought much to the party. But the opera did successfully depict the complex and often messy reality of living with HIV. The shift between grim reality and leaps of fantasy echoes the double perspective of HIV: it is a terrible disease, but it is also a call to arms, prompting debate over gay identity and liberation.

In the 1980s, HIV challenged gay sufferers in two ways – with the threat of death, and with having to reveal their sexuality. Nowadays, treatment is widely available, so much of the drama in Angels seems like a nightmare from a long time ago. But the stigma surrounding HIV remains: I still get calls from people with HIV whose families have abandoned them, or who are excluded from jobs, healthcare or school.

The opera’s penultimate line, “we will be citizens”, stayed with me. It’s a fitting tribute to those who endured the first terrible onslaught of the HIV epidemic. It stands as a challenge to change our attitudes to the disease.

Original Article

STAY UPDATED
Follow LASS on Twitter
or subscribe via email

Even without a cure, the end of the AIDS pandemic is in sight

A very bold statement to make in the run up to AIDS 2012, none the less, this is the view of Dr. Anthony Fauci, director of the National Institute of Allergy and Infections Diseases (NIAID )

NIAID director Dr. Anthony Fauci addressing the United Nations General Assembly special session on HIV/AIDS on 10June 2008.

Dr. Fauci was appointed Director of NIAID in 1984. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.  Dr. Fauci serves as one of the key advisors to the White House and Department of Health and Human Services on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza.

Dr. Fauci has made many contributions to basic and clinical research on the pathogenesis and treatment of immune-mediated and infectious diseases. He has pioneered the field of human immunoregulation by making a number of basic scientific observations that serve as the basis for current understanding of the regulation of the human immune response. In addition, Dr. Fauci is widely recognized for delineating the precise mechanisms whereby immunosuppressive agents modulate the human immune response. He has developed effective therapies for formerly fatal inflammatory and immune-mediated diseases such as polyarteritis nodosa, Wegener’s granulomatosis, and lymphomatoid granulomatosis. A 1985 Stanford University Arthritis Center Survey of the American Rheumatism Association membership ranked the work of Dr. Fauci on the treatment of polyarteritis nodosa and Wegener’s granulomatosis as one of the most important advances in patient management in rheumatology over the previous 20 years.

AN END TO NEW INFECTIONS?

Three decades into the AIDS pandemic an end to new infections is in sight, according to Dr. Fauci.

“We don’t even know if a cure is possible. What we know is it is possible that we can end this pandemic even without a cure,”

Fauci told AFP in an interview ahead of the International AIDS conference 22nd -27th July in Washington DC, America.

Some 34 million people around the world are living with human immunodeficiency virus, which has killed 25 million since it first emerged in the 1980s.

The theme of this conference, which is held every two years, is “Turning the Tide Together,” and is based on experts sharing knowledge of the latest advances and how to best implement them in order to halt new cases of HIV/AIDS.

“We have good and effective treatments but we have to keep people on the treatments indefinitely in order to keep them well,” said Dr. Fauci, referring to antiretroviral drugs which have transformed a deadly disease into a manageable condition.

“When you have a very marked diminution of the number of new infections then you reach what we call and AIDS-free generation.”

Dr. Fauci said he did not expect any staggering breakthroughs to be announced at the conference, but that the gain would come though collaborating on ideas to speed progress by using the tools that practitioners have already at hand.

Otherwise, if progress continues at the present rate of reducing new infections worldwide by about 1.5 percent per year, the goal becomes too distant, he said.

Recent studies that tested antiretroviral drugs in healthy people as a way to prevent getting HIV through sex with infected partners have shown some promise, though getting people to take their medication daily had proven a challenge.

“The important thing is you have to take your medication,” Fauci said, noting that average HIV risk reduction in a study of men who have sex with men was just 44 percent.

The approach of treating healthy people with antiretrovirals is known as pre-exposure prophylaxis, and “is not for everyone,” Fauci said. “We have to selectively use it.”

The US Food and Drug Administration on Monday approved the first pill for HIV prevention, Truvada, despite concerns by some in the health care community that it could encourage drug resistance and risky sex.

Novel ways to boost testing are also good news, particularly with the recent US approval of the first at-home HIV test.

“It is so important in the quest to ending the AIDS pandemic to get as many people tested as possible. You can link them to care and get them on treatment. Anything that makes that goal easier would be an important advance.”

As far as an AIDS vaccine, Fauci said researchers have made “good progress” but “still have a long way to go.”

Experts are examining a trial done in Thailand that showed in 2009 modest efficacy of just over 30 percent, but is still considered a breakthrough and offers clues for future study into why some were helped and others were not.

Dr. Fauci also said he did not expect much concern to be raised over upcoming reports of the extent of drug resistance to antiretrovirals.

“People may think I am taking it lightly but quite frankly it is not a serious problem,” Fauci said.

He added that overall, AIDS research is “going well” even though “funding is restricted right now.”

And he expressed pride in the United States’ President’s Emergency Plan for AIDS Relief (PEPFAR), “which has really transformed how you can get people in low income countries to get on treatment care and prevention.”

The United States provides almost half the world’s funding for international HIV assistance, according to UNAIDS.

The International AIDS Conference is returning to the United States after more than two decades away due to a ban on travel and immigration by people with HIV that was lifted in 2008 and signed into law in 2009.

Fauci called those restrictive laws “unfortunate” and “embarrassing.”

STAY UPDATED
Follow LASS on Twitter
or subscribe via email

PEP: THE BASICS

PEP: THE BASICS

PEP stands for Post Exposure Prophylaxis and is a treatment that may prevent HIV infection after the virus has entered the body.

Post = After
Exposure = A situation where HIV has a chance to get into someone’s bloodstream, like unsafe sex.
Prophylaxis = A treatment to stop an infection happening.

PEP Treatment: 

  • Involves taking anti-HIV drugs for four weeks
  • Must be started as soon as possible after unsafe sex or a condom not working, straight after exposure or within 24 hours is best and no later than 72 hours (three days)
  • Has side effects
  • Is likely to stop HIV but isn’t guaranteed to work

Where do I get PEP?

  • Sexual Health clinics (GUM clinics) – at Leicester Royal Infirmary or the one in your city / town
  • Hospital Accident & Emergency department (A&E) – be prepared to ask for PEP as soon as you can after you book in.
  • Not all of these places in every part of the country will have PEP or be able to prescribe it

PEP – Post Exposure Prophylaxis

How soon?

  • It is best to start PEP straight after exposure or within 24 hours and no later than 72 hours (three days later). The longer you wait there is less chance it will work, after 72 hours PEP isn’t usually given as it’s unlikely to work by then.

But if HIV is in my body doesn’t this mean I will now be infected?

  • No. After HIV gets into your bloodstream it takes from a few hours to a few days before it permanently infects you. If you act in that short time you stand a chance of stopping HIV before the infection takes hold.

How does PEP work?

  • Taking anti-HIV drugs every day for four weeks might stop the HIV before it gets a permanent hold in your body. PEP is not a ‘morning after’ pill that’s taken just once, it’s one month of drug treatment.

So if someone takes PEP they won’t become HIV positive?

  • Research shows PEP makes infection with HIV a lot less likely. But PEP doesn’t always work, some people who take it still end up with HIV after treatment. PEP can fail because some anti-HIV drugs don’t work against some strains of HIV. It’s more likely to fail if it’s not taken properly or soon enough.

Are the drugs the same as the ones taken by people with HIV?

  • Yes, you take three drugs which are also used in ‘combination therapy’ taken by HIV positive people.

Is PEP a cure for HIV?

  • There is no cure for HIV. PEP can only stop the HIV infection if it’s taken very soon after it has entered your body and before the infection takes hold. Once the HIV infection becomes permanent then anti-HIV drugs can’t get rid of the virus. This is because it is not in parts of the body the drugs can’t reach. Once HIV permanently infects someone the drugs can usually control the HIV in their body but can never get rid of it completely.

Does PEP have side effects?

  • Yes, it can cause diarrhoea, headaches, nausea and vomiting. Because of the side effects, you may need time off work or study and some people have to stop taking it. Side effects go once you stop taking the drugs. One Australian study showed that among people taking PEP, side effects were mild to moderate for two out of three people and severe for one in four.

What are the chances someone will get PEP?

  • New guidelines have been given to Sexual Health Clinics that help doctors decide if PEP should be given. A doctor will need to ask questions about:
  • Who you had unsafe sex with, to identify the likelihood of you having HIV.
  • What kind of sex you had, when it happened, whether it was oral, vaginal or anal sex and whether either of you came inside the other.
  • Doctors might sometimes give PEP after oral sex, depending on the circumstances.
  • It’s worth thinking about PEP if you or someone you had anal or vaginal sex with didn’t use a condom or something went wrong with the condom and it’s not later than 72 hours (3 days) since it happened.
  • They will also talk to you about having an HIV test. Before you are given PEP you must have a test to check you don’t already have HIV. You must also agree to be tested after taking PEP to see if it’s worked. PEP won’t be offered if you refuse to be tested.

What if I can’t get to a place that has PEP within 72 hours?

  • After 72 hours PEP won’t usually be offered so if it’s not possible to get to a Sexual Health Clinic in time it is advisable to go to a hospital Accident & Emergency department because they never close.

If I take PEP can I become resistant to HIV drugs so they won’t work if I get HIV later?

  • No, it’s HIV, not your body that can become resistant to the drugs. If PEP works it gets rid of the virus – and the virus can’t become resistant because it’s not there anymore. So if you were to become HIV positive later and needed drugs if wouldn’t make any difference that you took PEP in the past.
  • But if PEP doesn’t work and you become HIV positive, there may be problems with the HIV in your body being resistant to some drugs, including ones used in PEP.

If I’m taking PEP does that make me immune to HIV while I’m on it or when I’ve stopped taking it?

  • No. Unsafe sex while taking PEP could let more HIV into your body, making PEP much more likely not to work.
  • If, after taking PEP you have stayed HIV negative and then you have unsafe sex again, you can become infected just like any other HIV negative person.

Now we have PEP does it matter so much if I don’t use condoms?

  • PEP doesn’t change the need for condoms, here’s why:
  • Using a condom is more likely to stop HIV being passed on than PEP is.
  • Condoms don’t make you ill with side effects, which PEP can.
  • You need a condom for as long as the sex lasts – but PEP lasts for four weeks.
  • Condoms are everywhere. PEP can be hard – sometimes impossible – to get.
  • You control getting hold of condoms but doctors decide if you should get PEP and they may say no.

How many times can I have PEP?

  • Doctors decide who gets PEP and they’re unlikely to give these expensive and powerful drugs to the same person time after time. So if you keep having unsafe sex you will usually be offered help with having safer sex rather than being given PEP lots of times.
STAY UPDATED
Follow LASS on Twitter
or subscribe via email

HIV treatment breaks lead to drug resistance in the female genital tract

Antiretroviral treatment interruptions of 48 hours or more are associated with the emergence of resistant strains of HIV in the female genital tract, investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes.

The study included 102 women in Kenya who started first-line antiretroviral therapy based on a non-nucleoside reverse transcriptase inhibitor (NNRTI). Drug-resistant virus was detected in the genital tract of five women in the twelve months after treatment was started. Treatment interruptions were the most important risk factor for this outcome.

“We found that ART [antiretroviral therapy] adherence was a key determinant of genital tract resistance and that treatment interruptions of whatever cause lead to a substantial increase in the hazard of detecting genotypic resistance to antiretrovirals in female genital tract secretions,” write the authors. “Efforts to prevent treatment interruptions by improving program effectiveness, promoting adherence and timely refills, and avoiding the use of more toxic antiretroviral agents could therefore play an important role in reducing transmitted drug resistance.”

First-line HIV therapy often comprises two nucleoside reverse transcriptase inhibitors (NRTIs) combined with an NNRTI. This treatment can have a powerful and durable anti-HIV effect. However, it requires high levels of adherence. Drug-resistant strains of HIV can emerge with poorer adherence. Older drugs in the NNRTI class, nevirapine (Viramune) and efavirenz (Sustiva or Stocrin), have a low barrier to resistance.

Little is currently known about the emergence of drug-resistant virus in the genital tract of women treated with NNRTI-based therapy. This is an important gap in knowledge as drug-resistant virus is potentially transmissible.

Investigators therefore designed a prospective study involving women who started first-line HIV treatment in Mombasa between 2005 and 2008. During the first twelve months after starting therapy viral load was monitored at three-monthly intervals in both plasma and the genital tract. Samples with viral load above 1000 copies/ml were sent for resistance testing. The investigators conducted analysis to see which factors were associated with the emergence of drug-resistant virus in the genital tract.

Overall, the women had high levels of adherence to their antiretroviral therapy. Assessed by pill count, median adherence was 97%. However, there were 40 treatment interruptions. Their median duration was four days. Median pill-count adherence following treatment interruptions was just 83%.

Drug-resistant virus was detected in the blood of nine women (incidence, 10 per 100 person-years) and in the genital secretions of five individuals (incidence, 5.5 per 100 person-years). All five women with resistant HIV in their genital secretions also had resistant virus in their blood.

The investigators’ first set of analysis showed that a number of factors were associated with genital tract resistance. These included treatment interruptions (p = 0.006), pill-count adherence (p = 0.001) and a higher baseline viral load (p = 0.04).

But only treatment interruptions remained significant after controlling for potentially confounding factors. Interruptions were associated with a more than 14-fold increase in the risk of genital tract resistance (aHR = 14.2; 95% CI, 1.3-158.4; p = 0.03).

“The reasons for treatment interruption in this study included both unavoidable discontinuations due to drug toxicity or systemic illness and avoidable interruptions due to late refills, when it is likely that consecutive doses were missed,” note the investigators. “Despite a comprehensive program of adherence support including pre-ART counseling, directly administered therapy during the first month of treatment, a support group, pill boxes and transportation reimbursements, we were unable to prevent these events.”

Transport problems and pharmacy stock-outs have emerged as major barriers to adherence in resource-limited settings. The investigators are concerned that “such barriers may lead to the development of genital tract resistance due to treatment interruptions, suggesting an increased risk for transmission of drug-resistant virus”.

The Aids Library of Philadelphia FIGHT has a video on YouTube which explore the subject of HIV which is resistant to anti-HIV medications. Further information can be found on their website.

Original Article via NAM and Philadelphia Fight’s YouTube Channel

STAY UPDATED
Follow LASS on Twitter
or subscribe via email

The quest for a HIV vaccine

Credit: UNAIDS

There is broad scientific consensus that getting to zero new HIV infections will require an HIV vaccine. Modelling shows that even a partially effective HIV vaccine can save many lives and dollars over time.

Although a vaccine to prevent HIV could be the tool to quicken the pace to reach the end of AIDS, the quest for an effective vaccine has until now proved elusive. The very nature and variety of the human immunodeficiency virus has meant that it has resisted most attempts to quell its spread and scientists and vaccinologists the world over are focusing efforts on finding solutions.

Exciting recent developments in HIV vaccine research are instilling hope around finding an effective vaccine. In 2009, results from a trial in Thailand—RV144—showed a 31.2% vaccine efficacy in preventing HIV infections. Although only modestly protective, the results instilled new hope that an HIV vaccine could be found and made available for populations around the world most in need of a vaccine.

The results represented a significant scientific advance, and were the first demonstration that a vaccine can prevent HIV infection in a general adult population. It was a discovery of great importance and has been followed by more encouraging data in the last couple of years.

Data presented in the past year has been presented on the protective immune responses that were stimulated by the Thai vaccine trial.  Trials are now planned to see if an RV144-like regimen will protect against a strain of HIV infection found in South Africa and against HIV acquisition by people at higher risk of exposure, specifically men who have sex with men.

UNAIDS and the US Centers for Disease Control worked closely with modelling teams to estimate the impact of the RV144 regimen in different countries and with different populations and found that 10% of infections could be prevented if the same 31% efficacy was found in people who receive the vaccine. This shows that a modestly effective HIV vaccine could add to the prevention toolbox of partially effective methods, hastening the decline of the HIV epidemic.

These and other advances in HIV vaccine development—including the design of new tools and technologies for vaccine delivery—have boosted optimism in the field about the prospects for the development of a safe and effective AIDS vaccine.

However, early data from the HIV Vaccines and Microbicides Resource Tracking Working Group is showing that a downturn in HIV vaccine funding that began in 2008 continued through 2011. The quest for effective HIV vaccines is a long-term investment in both the product (vaccines) and in the people who will develop, produce, market and support them. Investments in research and trials are essential and can bring benefits far beyond the AIDS field.

The need for a vaccine to prevent HIV is clear.  There are in excess of 34 million people living with HIV, and every day more than 7000 people are becoming newly infected with the virus. Although a vaccine may not provide the magic bullet to end the AIDS epidemic, it would provide an additional tool to add to the robust package of HIV prevention options which are now available.

UNAIDS will continue to work with multiple partners––scientific communities, national and international AIDS research agencies, the pharmaceutical industry, private foundations, member states, and affected communities––to push the HIV vaccine agenda forward and ensure that the quest for a safe and effective HIV vaccine continues.

Original Article via UNAids

STAY UPDATED
Follow LASS on Twitter

or subscribe via email
Related articles

Aging & HIV

There’s no denying the life-extending benefits of antiretroviral therapy. While it has allowed many people living with HIV to plan for their golden years, it has also meant preparing to face age-related health problems. According to the CDC, 25 percent of those living with the virus are over 50 years old.  In turn, there’s a growing need for comprehensive  care to prevent and manage typical age-related maladies, such as heart disease, cancer, diabetes and osteoporosis—all of which can be complicated by HIV and its treatment.
You can find comprehensive information about treatment options from your GP and the people over at http://www.aidsmeds.com have written an excellent report into HIV & Ageing covering:
  • What is aging, and why do we become ill as we get older?
  • How does HIV affect the aging process?
  • Are people with HIV aging more rapidly?
  • Is it possible to slow down the aging process?
  • Are there experimental treatments to slow aging in people with HIV?

The good news is that most HIV-positive people can do quite a lot to slow the aging process and guard against the onset of age-related illness. So why not head over there and understand how aging works in the first place, and what you can do to help yourself..

STAY UPDATED
Follow LASS on Twitter

or subscribe via email
 Related articles